Moving projects along the pipeline

Pfizer has moved a high proportion of its projects from one stage of development to the next in the last two years.

Summary 

  • What: Pfizer has moved almost all its R&D projects that target needs of populations in low- and middle-income countries from one stage of development to the next over the past two years.
  • Objective: Moving projects along the pipeline demonstrates a company’s continued commitment to invest in R&D that meets the needs of populations in countries in scope of the Index.
  • Details: This is relevant to all products in Pfizer’s R&D pipeline that target needs of populations in low- and middle-income countries.
  • Example: Notably, Pfizer received approval for its meningococcal serogroup B vaccine (Trumenba®) and a label update that allows women to self-inject the contraceptive medroxyprogesterone acetate (Sayana Press®).

Looking closer

Of the 20 companies measured in the Index, Pfizer is a leader at moving relevant projects along the pipeline: a high proportion of its relevant pipeline moved from one stage of clinical development to the next since the previous period of analysis. Moving projects along the pipeline demonstrates a company’s continued commitment to invest in R&D that meets the needs of populations in countries in scope of the Index. It also demonstrates their success at such product development.

Notably, Pfizer’s group B streptococcus vaccine moved from discovery into pre-clinical development in the last two years. It also has four investigational medicines that moved from pre-clinical to clinical development, targeting diabetes, HIV, ischaemic heart disease and schizophrenia. Further, it is developing vaccines for C. difficile and MRSA infections that moved from phase I to phase II clinical trials in the past two years. In October 2014, Pfizer received US FDA approval for its meningococcal serogroup B vaccine (Trumenba®), the first of its kind to be approved in the USA. Pfizer also received UK approval for an update to the label for medroxyprogesterone acetate (Sayana Press®) in 2015, allowing women to administer the long-acting contraceptive by self-injection. Pfizer aims to introduce this label update outside the EU, initially focusing on countries such as Burkina Faso, Senegal and Uganda, where the company has identified unmet need and demand for injectable contraceptives.

Sign up to receive updates about our work.